Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Decreases By 13.2%

Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 576,400 shares, a decline of 13.2% from the January 15th total of 664,400 shares. Based on an average daily trading volume, of 462,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 21.8% of the company's shares are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $75.00 price target on shares of Aligos Therapeutics in a report on Thursday, November 7th.

Institutional Investors Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC grew its holdings in Aligos Therapeutics by 2,073.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company's stock valued at $26,000 after purchasing an additional 622 shares during the period. AlphaMark Advisors LLC grew its holdings in Aligos Therapeutics by 1,000.0% in the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company's stock valued at $44,000 after purchasing an additional 1,000 shares during the period. Golden State Wealth Management LLC purchased a new stake in Aligos Therapeutics in the fourth quarter valued at approximately $107,000. Northern Trust Corp purchased a new stake in Aligos Therapeutics in the fourth quarter valued at approximately $205,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Aligos Therapeutics by 19.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company's stock valued at $569,000 after purchasing an additional 2,306 shares during the period. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Aligos Therapeutics Trading Down 6.4 %

Shares of NASDAQ ALGS traded down $1.42 during midday trading on Thursday, reaching $20.85. 138,995 shares of the stock were exchanged, compared to its average volume of 297,754. The company has a market capitalization of $74.85 million, a P/E ratio of -1.57 and a beta of 2.45. Aligos Therapeutics has a 52-week low of $6.76 and a 52-week high of $46.80. The stock has a 50 day moving average price of $32.06 and a 200-day moving average price of $20.26.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).